NSI-189
Hippocampal neurogenesis.
- Sizes available
- —
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
Hippocampal neurogenesis. Phase 2 depression clinical research.
Mechanism · Small molecule. Hippocampal BDNF / neurogenesis modulator. Note: not peptide.
Best for. Not for.
Best for
- Hippocampal neurogenesis research
- Depression alternative protocol users (off-label)
- Oral capsule users on
Not for
- Phase 2 MDD trial. Primary endpoint missed 2017
- Pregnancy or nursing
- Severe psychiatric disorder (supervision required)
- Long-term safety is not established (no commercial product)
Mechanism, dose, ramp, risk.
- Mechanism
- Stimulates hippocampal neurogenesis. Phase 2 trial for depression.Source · PEPVERA editorial
- Target dose
- 40-80 mg / day, oral.Source · PEPVERA editorial
- Ramp
- Cycles.Source · PEPVERA editorial
- Risks
- Limited long-term data.Source · PEPVERA editorial
Compared to its siblings.
NSI-189
Hippocampal neurogenesis. Phase 2 depression clinical research.
Pros
- · No IM injection required, unlike cerebrolysin.
Cons
- · No 50+ country regulatory approval like cerebrolysin.
Cerebrolysin
EU approved. Neurotrophic mix.
Pros
- · 50+ Country approval
Cons
- · IM injection
See Cerebrolysin →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 0 suppliers
No verified suppliers yet for this compound.
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
40-80 mg / day, oral.
Initiation
Week 3–4
40-80 mg / day, oral.
Signal emerges
Week 5–8
40-80 mg / day, oral.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
4 mg = 0.20 mL at 20.00 mg/mL. 10.0 doses per vial.
mind · III
NSI-189 · 40mg